2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Active not recruiting
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
1131
Neoplasms
986
Carcinoma, Non-Small-Cell Lung
903
Prostatic Neoplasms
595
Neoplasm Metastasis
529
Leukemia, Myeloid, Acute
514
Colorectal Neoplasms
492
Lung Neoplasms
490
Melanoma
488
Multiple Myeloma
478
Pancreatic Neoplasms
387
Lymphoma
370
Ovarian Neoplasms
368
Recurrence
365
Lymphoma, Non-Hodgkin
348
Leukemia
340
Leukemia, Lymphocytic, Chronic, B-Cell
322
Precursor Cell Lymphoblastic Leukemia-Lymphoma
291
Head and Neck Neoplasms
276
Carcinoma, Renal Cell
276
Brain Neoplasms
276
Carcinoma, Hepatocellular
261
Glioblastoma
250
Myelodysplastic Syndromes
244
Lymphoma, Large B-Cell, Diffuse
244
Squamous Cell Carcinoma of Head and Neck
241
Lymphoma, Follicular
236
Colonic Neoplasms
214
Stomach Neoplasms
200
Rectal Neoplasms
190
Interventions
SLC-0111
1
IFL protocol
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Metastatic Pancreatic Ductal Adenocarcinoma
×
Clear all
NCT03450018
2024-05-24
SLC-0111-17-01
British Columbia Cancer Agency
Phase 1/2
Terminated
6 enrolled
NCT03331640
2022-01-11
PANTHEON
AIO-Studien-gGmbH
Phase 2
Terminated
67 enrolled